Insights

Expanding Product Portfolio Eikon Therapeutics recently acquired preclinical assets from Cleave Therapeutics, expanding its product portfolio with a large chemical library spanning multiple targets in the AAA family of ATPases. This acquisition opens up new sales opportunities for Eikon Therapeutics to offer innovative solutions to address unmet medical needs.

Strategic Partnerships Driving Growth Through partnerships with companies like Impact Therapeutics for the development and commercialization of PARP1 selective inhibitors, Eikon Therapeutics is strategically positioning itself for growth. These collaborations create avenues for joint sales efforts, leveraging the strengths of each partner to access new markets and drive revenue growth.

Leveraging Technology for Competitive Edge Eikon Therapeutics utilizes cutting-edge technology such as microscopes enabling real-time, molecular-resolution measurements of protein movement in living cells. By leveraging advanced technology in their drug discovery process, Eikon Therapeutics can showcase its innovative solutions to potential clients, highlighting the competitive edge it brings to the market.

Recent Financing for Expansion With a recent funding of $106 million in Series C, Eikon Therapeutics has the financial resources to support its expansion plans. This funding can facilitate the scaling of sales operations, investment in marketing initiatives, and expanding reach to new markets, providing ample opportunities for increased sales revenue.

Board Appointments for Industry Credibility Eikon Therapeutics has appointed industry experts like Robin L. Washington and Robert L. Huffines to its Board of Directors. These appointments not only enhance the company's credibility but also open doors to new business relationships. Leveraging the reputation and expertise of these board members can facilitate meaningful sales discussions and partnerships.

Eikon Therapeutics Tech Stack

Eikon Therapeutics uses 8 technology products and services including AutoCad, jsDelivr, Exhibit, and more. Explore Eikon Therapeutics's tech stack below.

  • AutoCad
    Cad & Graphics
  • jsDelivr
    Content Delivery Network
  • Exhibit
    Javascript Graphics
  • Microsoft
    Miscellaneous
  • Splunk
    Miscellaneous
  • Python
    Programming Languages
  • Jobvite
    Recruitment Marketing
  • Django
    Web Frameworks

Media & News

Eikon Therapeutics's Email Address Formats

Eikon Therapeutics uses at least 1 format(s):
Eikon Therapeutics Email FormatsExamplePercentage
lastf@eikontx.comDoeJ@eikontx.com
55%
first@eikontx.comJohn@eikontx.com
18%
first.last@eikontx.comJohn.Doe@eikontx.com
15%
lf@eikontx.comDJ@eikontx.com
12%

Frequently Asked Questions

Where is Eikon Therapeutics's headquarters located?

Minus sign iconPlus sign icon
Eikon Therapeutics's main headquarters is located at 3929 Point Eden Way Hayward, CA 94545 US. The company has employees across 5 continents, including North AmericaEuropeSouth America.

What is Eikon Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Eikon Therapeutics's official website is eikontx.com and has social profiles on LinkedIn.

How much revenue does Eikon Therapeutics generate?

Minus sign iconPlus sign icon
As of July 2024, Eikon Therapeutics's annual revenue reached $35M.

What is Eikon Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Eikon Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Eikon Therapeutics have currently?

Minus sign iconPlus sign icon
As of July 2024, Eikon Therapeutics has approximately 370 employees across 5 continents, including North AmericaEuropeSouth America. Key team members include Chief People Officer: B. H. S.Chief Financial Officer: A. F. B.Chief Business Officer & General Counsel: B. T.. Explore Eikon Therapeutics's employee directory with LeadIQ.

What industry does Eikon Therapeutics belong to?

Minus sign iconPlus sign icon
Eikon Therapeutics operates in the Biotechnology Research industry.

What technology does Eikon Therapeutics use?

Minus sign iconPlus sign icon
Eikon Therapeutics's tech stack includes AutoCadjsDelivrExhibitMicrosoftSplunkPythonJobviteDjango.

What is Eikon Therapeutics's email format?

Minus sign iconPlus sign icon
Eikon Therapeutics's email format typically follows the pattern of . Find more Eikon Therapeutics email formats with LeadIQ.

How much funding has Eikon Therapeutics raised to date?

Minus sign iconPlus sign icon
As of July 2024, Eikon Therapeutics has raised $106M in funding. The last funding round occurred on Jun 01, 2023.

When was Eikon Therapeutics founded?

Minus sign iconPlus sign icon
Eikon Therapeutics was founded in 2019.
Eikon Therapeutics

Eikon Therapeutics

Biotechnology ResearchCalifornia, United States201-500 Employees

Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the interface of biology, engineering and chemistry to discover novel treatments for life-threatening diseases. Eikon’s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes which enable real time, molecular-resolution measurements of protein movement in living cells. 

By directly measuring the effects of chemical compounds on the behavior of protein molecules in a live cellular environment, Eikon’s landmark assays facilitate the highly sensitive identification of compound-protein interactions that could not be identified through traditional assays, thereby unlocking otherwise intractable classes of proteins as drug targets. Furthermore, the ability to directly visualize protein mechanisms in disease coupled with the extraordinarily high-powered high-content data sets generated by Eikon’s drug-screening technology enable an unprecedented opportunity to quantitatively explore novel biology in the living cell. These insights facilitate creation and application of data-driven hypotheses to the discovery of life-saving therapies. 

Eikon is seeking adventurous, passionate and creative team members eager to apply their talents to empower interdisciplinary scientific exploration, inaugurate a radical drug-discovery paradigm, and ultimately create novel medicines. To learn more about open positions, please visit:  https://eikontx.com/team#positions

Section iconCompany Overview

Headquarters
3929 Point Eden Way Hayward, CA 94545 US
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2019
Employees
201-500

Section iconFunding & Financials

  • $106M

    Eikon Therapeutics has raised a total of $106M of funding over 4 rounds. Their latest funding round was raised on Jun 01, 2023.

  • $10M$50M

    Eikon Therapeutics's revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $106M

    Eikon Therapeutics has raised a total of $106M of funding over 4 rounds. Their latest funding round was raised on Jun 01, 2023.

  • $10M$50M

    Eikon Therapeutics's revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.